Literature DB >> 9554639

Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH.

Y Aelony1, R R King, C Boutin.   

Abstract

STUDY
OBJECTIVE: To determine the effectiveness of pleurodesis by thoracoscopic talc poudrage (TTP) in patients with low pH malignant pleural effusions.
DESIGN: Review of prospectively collected data on all thoracoscopic procedures performed from 1982 to 1996. PATIENTS AND
SETTING: Twenty-five members in a prepaid, closed-panel health maintenance organization, whose malignant pleural effusion pH was < or = 7.30.
INTERVENTIONS: Pleural fluid pH was measured prior to diagnostic and therapeutic, single puncture, rigid thoracoscopy, under local anesthesia, in an operating room. MEASUREMENTS AND
RESULTS: Success of pleurodesis was determined with serial radiographs at 10 days, 30 days, and frequent intervals until death or up to 1 year following the procedure. Failure was indicated by evidence of recurrent fluid or persistence of a space between the visceral and parietal pleura. Morbidity of the procedure, days of chest tube drainage, and days of hospitalization were recorded concurrently during hospitalization and outpatient follow-up. Fifty of the 76 patients found to have a pleural pH measurement had a pleural pH >7.30, averaging 7.37 (7.31 to 7.55). The other 26 patients (34%) with pH < or = 7.30 (low pH) are the subjects of this study, of whom 25 were evaluable. Pleurodesis was successful in 22 of 25 (88%), although 4 died prior to 30 days. The three failures all had trapped lung. Chest tube drainage averaged 3.2+/-1.3 days, which approximated the time of hospitalization (3.3+/-1.1 days). There were no thoracoscopy-related deaths; significant morbidity occurred only in one patient with trapped lung, who had prolonged chest tube drainage before and after TTP, and eventually developed empyema.
CONCLUSIONS: TTP is an effective pleurodesis technique in malignant pleural effusions, even when the pleural pH is low. The short hospital stay and high success rate make this approach a good choice in palliating symptomatic malignant pleural effusions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554639     DOI: 10.1378/chest.113.4.1007

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Pleural fluid findings as prognostic factors for malignant pleural mesothelioma.

Authors:  Tanseli Efeoglu Gonlugur; Ugur Gonlugur
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

2.  Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.

Authors:  Carolyn M Dresler; Jemi Olak; James E Herndon; William G Richards; Ernest Scalzetti; Stewart B Fleishman; Kemp H Kernstine; Todd Demmy; David M Jablons; Leslie Kohman; Thomas M Daniel; George B Haasler; David J Sugarbaker
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

Review 3.  Malignant pleural effusions: appropriate treatment approaches.

Authors:  Yener Aydin; Atila Turkyilmaz; Yavuz Selim Intepe; Atilla Eroglu
Journal:  Eurasian J Med       Date:  2009-12

4.  Sodium hydroxide as a sclerosing agent in patients with neoplastic pleural effusion non-candidates for VATS: results of a minimally invasive protocol.

Authors:  Micaela Raices; Matías E Czerwonko; Agustin Dietrich; Alejandro Da Lozzo; Enrique Beveraggi; David Smith
Journal:  Updates Surg       Date:  2017-08-31

5.  Does pleural fluid appearance really matter? The relationship between fluid appearance and cytology, cell counts, and chemical laboratory measurements in pleural effusions of patients with cancer.

Authors:  Bulent Ozcakar; Carlos H Martinez; Rodolfo C Morice; Georgie A Eapen; David Ost; Mona G Sarkiss; Hsienchang T Chiu; Carlos A Jimenez
Journal:  J Cardiothorac Surg       Date:  2010-08-18       Impact factor: 1.637

6.  Predictors of survival in non-small cell lung cancer patients with pleural effusion undergoing thoracoscopy.

Authors:  Li-Xu Xie; Xing-Guang Wang; Wen-Jie You; Xiao-Bin Ma; Yong-Gang Wang; Ting-Ting Liu; Shu-Juan Jiang
Journal:  Thorac Cancer       Date:  2019-05-15       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.